Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.

Journal for immunotherapy of cancer - 1 Mar 2021

Cecil Denise, Park Kyong Hwa, Curtis Benjamin, Corulli Lauren, Disis Mary Nora

Abstract excerpt

BACKGROUND: The most common clinical outcome observed after treatment with immune checkpoint inhibitor antibodies is disease stabilization. Using vaccines to generate high levels of tumor antigen-specific T-helper 1 (Th1), we show that tumors not eradicated by vaccination demonstrate prolonged disease stabilization. We evaluated the mechanism by which type I T cells inhibit disease progression and potentially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphocytes, Tumor-Infiltrating

Share to Oncogene Proteins

Share to Paclitaxel

Share to Th1 Cells

Share to Tumor Burden

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33762321
DOI: 10.1136/jitc-2021-002355
PMCID: PMC7993179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.PMID 33762321Read ↗

Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune SurveillanceSemantic proximity Read ↗

COVID-19 Vaccines: Bolstering Cancer TreatmentSemantic proximity Read ↗

Advancement insights in cancer vaccines: mechanisms, types, and clinical applicationsSemantic proximity Read ↗

Combinatorial Immunotherapies Overcome MYC-Driven Immune EvasionSemantic proximity Read ↗

MYC promotes immune-suppression in TNBC via inhibition of IFN signalingSemantic proximity Read ↗

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined TherapiesSemantic proximity Read ↗

IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapySemantic proximity Read ↗

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancerSemantic proximity Read ↗

Eradication of tumors with pre-existing antigenic heterogeneity by vaccine-mediated co-engagement of CAR T and endogenous T-cellsSemantic proximity Read ↗

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.Semantic proximity Read ↗

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 AntibodySemantic proximity Read ↗

Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.